3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
43
Triple Negative Breast Neoplasms
19
Breast Neoplasms
15
Carcinoma, Non-Small-Cell Lung
14
Neoplasm Metastasis
10
Lung Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasms
6
Adenocarcinoma
6
Cholangiocarcinoma
5
Stomach Neoplasms
4
Gallbladder Neoplasms
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Pancreatic Adenocarcinoma
3
Ovarian Neoplasms
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Rectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Pancreatic Ductal
2
Carcinoma, Hepatocellular
2
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non Small Cell Lung Cancer NSCLC
×
Albumin-Bound Paclitaxel
×
1 year
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA